Author:
Cornejo Agustin,Bohnenblust Mary,Harris Catherine,Abrahamian Gregory A.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference10 articles.
1. Kremers WK, Devarbhavi HC, Wiesner RH, Krom RA, Macon WR, Habermann TM (2006) Post-transplant lymphoproliferative disorders following liver transplantation: incidence, risk factors and survival. Am J Transplant 6(5 Pt 1):1017–1024
2. Svoboda J, Kotloff R, Tsai DE (2006) Management of patients with post-transplant lymphoproliferative disorder: the role of rituximab. Transpl Int 19(4):259–269
3. Hsu YC, Liao WC, Wang HP, Yao M, Lin JT (2007) Catastrophic gastrointestinal manifestations of post-transplant lymphoproliferative disorder. Dig Liver Dis 13 December [Epub ahead of print]
4. Kollmar O, Becker S, Schilling MK, Maurer CA (2002) Intestinal lymphoma perforations as a consequence of highly effective anti-CD20 antibody therapy. Transplantation 73(4):669–670
5. (No authors listed) (2002) Rituximab: first report of intestinal perforations in an elderly patient: case report. Reactions. 2002:1(901):14–15(2)
Cited by
25 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献